Showing results (181-190 of 189) with videos related to

Sort By:
Pageof 19
You have reached the last page of results.This site can display upto 189 results.
Lung Cancer (Amsterdam, Netherlands)|November 29, 2020
PTEN, ATM, IDH1 mutations and MAPK pathway activation as modulators of PFS and OS in patients treated by first line EGFR TKI, an ancillary study of the French Cooperative Thoracic Intergroup (IFCT) Biomarkers France projectH Blons, J-B Oudart, J-P Merlio, et al.
Clinical Rheumatology|May 25, 2020
Cachexia in patients with rheumatoid arthritis: a cohort studyRafaela Ce Santo, Jordana Ms Silva, Priscila S Lora, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 18, 2015
Randomized phase II-III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial†J-L Pujol, A Lavole, E Quoix, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 5, 2019
Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trialD Moro-Sibilot, N Cozic, M Pérol, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 22, 2020
Vemurafenib in non-small-cell lung cancer patients with BRAF<sup>V600</sup> and BRAF<sup>nonV600</sup> mutationsJ Mazieres, C Cropet, L Montané, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 25, 2021
Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy - results from the randomised phase II ETOP/IFCT 4-12 STIMULI trialS Peters, J-L Pujol, U Dafni, et al.
ESMO Open|October 16, 2025
Innovative therapeutic cancer vaccine PDC<sup>∗</sup>lung01 with or without anti-PD-1: an open-label, dose-escalation phase I/II study in non-small-cell lung cancerJ Vansteenkiste, I Demedts, K Cuppens, et al.
Bulletin Du Cancer|May 24, 2001
[Standards, options and recommendations for the management of locally advanced non small cell lung carcinoma]E Bardet, D Moro-Sibilot, T Le Chevalier, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|August 28, 2001
[Standards, Options and Recommendations for the management of stage I or II primary bronchial cancers treated exclusively with radiotherapy]E Touboul, J L Lagrange, S Theobald, et al.
Pageof 19